Updates are available Correction dated 2023-10-03

Article History

Received: 10 July 2023

Revised: 16 July 2023

Accepted: 7 August 2023

First Online: 17 August 2023

Change Date: 3 October 2023

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1038/s41375-023-02017-5

Competing interests

: EJ: Employment with AstraZeneca; MS, MG, PL, AR, CP, NJ, CW, KH, NS, JK, AB, SN have nothing to disclose; PF: Honoraria from BMS, Novartis, Jazz, Abbvie, Agios, Servier, Research support (as Groupe Francophone des Myélodysplasies chairperson) : BMS, Novartis, Jazz, Abbvie, Agios, Servier, GJR: Consultancy: Abbvie, Amgen, Argenx, AstraZeneca, Bluebird Bio, Blueprint Medicines, Bristol-Myers Squibb, Caribou Biosciences, Celgene, Daiichi Sankyo, Ellipses Pharma, GlaxoSmithKline, Janssen, Jasper Pharmaceuticals, Jazz Pharmaceuticals, Molecular Partners, Novartis, Pfizer, Roche, Syndax, Takeda (IRC Chair); LB advisory role or expert testimony – Abbvie, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Pfizer; Honoraria – Abbvie, Amgen, Astellas, Bristol-Myers Squibb, Celgene, Daiichi Sankyo, Janssen, Jazz Pharmaceuticals, Novartis, Pfizer, Sanofi; Financing of scientific research – Bayer, Jazz Pharmaceuticals. HNK: Employment with Astex Pharmaceuticals, Inc.; YH, MA: Consultancy for Astex Pharmaceuticals, Inc.; KD: Advisory role for Amgen, Bristol-Myers Squibb, Celgene, Janssen, Jazz Pharmaceuticals, Novartis, Roche, Daiichi Sankyo; research funding from: Agios, Astex, Astellas, Bristol-Myers Squibb, Celgene, Kronos-Bio, Novartis; HD: Advisory role for Abbvie, Agios, Amgen, Astellas, AstraZeneca, Berlin-Chemie, Bristol-Myers Squibb, Celgene, GEMoaB, Gilead, Janssen, Jazz Pharmaceuticals, Novartis, Syndax; research funding from Abbvie, Agios, Amgen, Astellas, Bristol-Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis.